Skip to main content
main-content
Erschienen in: DNP – Die Neurologie & Psychiatrie 4/2022

01.08.2022 | Epilepsie | Zertifizierte Fortbildung

Cenobamat, Cannabidiol und Fenfluramin

Was können die neuen anfallssupprimierenden Medikamente?

verfasst von: Dr. med. Georg Leonhardt

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 4/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Der medikamentöse Baukasten für konvulsive Anfälle und Epilepsien bietet Ärzten viele neue wirksame Substanzen. Auch seltene Erkrankungen wie das Dravet-Syndrom oder das Lennox-Gastaut-Syndrom profitieren von den neuen Wirkstoffen.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Eadie MJ. Sir Charles Locock and potassium bromide. J R Coll Physicians Edinb. 2012;42(3):274-9. Eadie MJ. Sir Charles Locock and potassium bromide. J R Coll Physicians Edinb. 2012;42(3):274-9.
2.
Zurück zum Zitat Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs. 2021;35(9):935-63. Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs. 2021;35(9):935-63.
3.
Zurück zum Zitat Keam SJ. Cenobamate: First Approval. Drugs. 2020;80(1):73-8. Keam SJ. Cenobamate: First Approval. Drugs. 2020;80(1):73-8.
4.
Zurück zum Zitat Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311-22. Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311-22.
5.
Zurück zum Zitat Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38-48. Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38-48.
6.
Zurück zum Zitat Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099-108. Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099-108.
7.
Zurück zum Zitat Brandt C, Sánchez-Álvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86-93. Brandt C, Sánchez-Álvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86-93.
8.
Zurück zum Zitat Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav EB. 2022;126:108429. Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav EB. 2022;126:108429.
9.
Zurück zum Zitat Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783-6. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783-6.
10.
Zurück zum Zitat Gaston TE, Szaflarski JP. Cannabis for the Treatment of Epilepsy: an Update. Curr Neurol Neurosci Rep. 8. 2018;18(11):73. Gaston TE, Szaflarski JP. Cannabis for the Treatment of Epilepsy: an Update. Curr Neurol Neurosci Rep. 8. 2018;18(11):73.
11.
Zurück zum Zitat Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-20. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-20.
12.
Zurück zum Zitat Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-21. Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-21.
13.
Zurück zum Zitat Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018;378(20):1888-97. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018;378(20):1888-97.
14.
Zurück zum Zitat Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2018;391(10125):1085-96. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2018;391(10125):1085-96.
15.
Zurück zum Zitat Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021;78(3):285-92. Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021;78(3):285-92.
16.
Zurück zum Zitat Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, u. a. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10216):2243-54. Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, u. a. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10216):2243-54.
17.
Zurück zum Zitat Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020;77(3):300-8. Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020;77(3):300-8.
18.
Zurück zum Zitat Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG et al. Successful use of fenfluramine as an Add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131-9. Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG et al. Successful use of fenfluramine as an Add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131-9.
19.
Zurück zum Zitat Specchio N, Pietrafusa N, Ferretti A, Trivisano M, Vigevano F. Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome. Epilepsia. 2020;61(4):831-3. Specchio N, Pietrafusa N, Ferretti A, Trivisano M, Vigevano F. Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome. Epilepsia. 2020;61(4):831-3.
Metadaten
Titel
Cenobamat, Cannabidiol und Fenfluramin
Was können die neuen anfallssupprimierenden Medikamente?
verfasst von
Dr. med. Georg Leonhardt
Publikationsdatum
01.08.2022
Verlag
Springer Medizin
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 4/2022
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-022-4935-3